May 16, 2025
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
May 12, 2025
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings
May 01, 2025
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
Apr 02, 2025
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
Feb 24, 2025
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
Feb 19, 2025
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
Feb 05, 2025
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET
Jan 13, 2025
BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
Jan 06, 2025
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA
Nov 16, 2024
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
Oct 29, 2024
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
Sep 04, 2024
BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
Sep 04, 2024
BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time
Aug 29, 2024
BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY
Aug 21, 2024
BioMarin Announces New R&D and Business Development Leadership
Aug 19, 2024
BioMarin to Host 2024 Investor Day on September 4th in New York
Jun 17, 2024
BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health
May 08, 2024
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
Mar 12, 2024
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Mar 07, 2024
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer